Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients — XQonc-007

Advanced Non-squamous Non-small-cell Lung Cancer Clinical Trial

Official title:
Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed After First - Line Induction Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer: A Prospective, Open, Single Arm Clinical Study

Status Withdrawn

Clinical Trial Summary

Lung cancer is a malignant tumor that causes the highest morbidity and mortality, and the main pathological type is non-small cell lung cancer (NSCLC). Most of them present with advanced stage at diagnosis. This design is to study maintenance therapy with pemetrexed plus apatinib after first line induction therapy four cycles for advanced non-squamous non-small-cell lung cancer. XQonc-0007

Clinical Trial Description

XQonc-0007 ;

Study Design

Related Conditions & MeSH terms

Advanced Non-squamous Non-small-cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms

Clinical Trial Details

NCT number	NCT03190239
Study type	Interventional
Source	Xinqiao Hospital of Chongqing
Contact
Status	Withdrawn
Phase	Phase 2
Start date	July 15, 2017
Completion date	July 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04959981` - A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC	Phase 1
Not yet recruiting	`NCT06028633` - Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients	Phase 2
Not yet recruiting	`NCT06463665` - Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)	Phase 2
Not yet recruiting	`NCT06416410` - JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation	Phase 3
Withdrawn	`NCT03792503` - Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen	Phase 4
Recruiting	`NCT05648071` - First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial	Phase 3
Recruiting	`NCT04416035` - A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC	Phase 3